Amgen Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen or view top-rated stocks.

14 Wall Street research analysts have issued twelve-month price objectives for Amgen's stock. Their AMGN stock forecasts range from $185.00 to $290.00. On average, they expect Amgen's stock price to reach $242.57 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts' price targets for Amgen or view top-rated stocks among Wall Street analysts.

Amgen's stock was trading at $224.97 at the beginning of 2022. Since then, AMGN stock has increased by 9.1% and is now trading at $245.55.
View the best growth stocks for 2022 here.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Amgen.

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Wednesday, April, 27th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $4.22 by $0.03. The medical research company had revenue of $6.24 billion for the quarter, compared to analysts' expectations of $6.09 billion. Amgen had a net margin of 21.75% and a trailing twelve-month return on equity of 165.95%. During the same period in the prior year, the firm posted $3.70 EPS.
View Amgen's earnings history.

Amgen announced a quarterly dividend on Wednesday, March 2nd. Stockholders of record on Tuesday, May 17th will be given a dividend of $1.94 per share on Wednesday, June 8th. This represents a $7.76 annualized dividend and a dividend yield of 3.16%. The ex-dividend date is Monday, May 16th.
View Amgen's dividend history.

Amgen(NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 3.19%. Amgen has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Amgen is 76.38%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Amgen will have a dividend payout ratio of 40.97% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

Amgen updated its FY22 earnings guidance on Wednesday, April, 27th. The company provided earnings per share guidance of $17.00-18.00 for the period, compared to the consensus estimate of $17.61. The company issued revenue guidance of $25.4-26.5 billion, compared to the consensus revenue estimate of $26.09 billion.

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amgen include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS).
View all of AMGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Chemung Canal Trust Co. (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends for Amgen.

AMGN stock was purchased by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co..
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $245.55.

Amgen (NASDAQ:AMGN) has a market capitalization of $131.17 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $10.16 on an earnings per share basis.

Amgen employs 24,200 workers across the globe.

Amgen was founded in 1980.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for Amgen is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at [email protected], or via fax at 805-447-1010.